Sulfaphenazole: Benchmark CYP2C9 Inhibitor for Drug Metabolism and Vascular Research

Executive Summary: Sulfaphenazole is a potent, competitive inhibitor of the cytochrome P450 enzyme CYP2C9, exhibiting a Ki of 0.3 ± 0.1 μM and high selectivity over related isoforms (APExBIO). It modulates drug metabolism by competitively binding the CYP2C9 active site, impacting pharmacogenetic outcomes and adverse drug reaction studies (Turner et al., 2022). In vivo, sulfaphenazole restores endothelial function in diabetic mouse models by reducing oxidative stress and increasing nitric oxide bioavailability. Its physicochemical properties—water insolubility, high DMSO/ethanol solubility, and -20°C storage—support diverse workflow integration. APExBIO's sulfaphenazole is validated for scientific research, not clinical or diagnostic use.

Biological Rationale

Cytochrome P450 enzymes (CYPs) are central to hepatic drug metabolism and the bioactivation or detoxification of xenobiotics. CYP2C9, in particular, is responsible for the metabolic clearance of up to 15% of clinically used drugs, including warfarin, phenytoin, tolbutamide, and various NSAIDs (Turner et al., 2022). Genetic polymorphisms in CYP2C9 directly influence drug response variability and adverse drug reaction risk. Precise inhibition of CYP2C9 enables the dissection of isoform-specific metabolic pathways and facilitates pharmacogenetic research. Sulfaphenazole, a sulfonamide antibiotic, is uniquely suited for competitive CYP2C9 inhibition in preclinical and mechanistic studies (see detailed review—this article expands on in vivo benchmarks and translational potential).

Mechanism of Action of Sulfaphenazole

Sulfaphenazole acts as a highly selective, competitive inhibitor of CYP2C9. It binds reversibly to the enzyme's active site, blocking substrate access and preventing oxidation of target drugs (APExBIO). The reported inhibition constant (Ki) for CYP2C9 is 0.3 ± 0.1 μM, indicating high affinity. Sulfaphenazole exhibits markedly weaker inhibition against CYP2C8 and CYP2C18 and shows no measurable inhibition for CYP1A1, CYP1A2, CYP3A4, or CYP2C19 at comparable concentrations. This selectivity is critical for dissecting CYP2C9-specific metabolic and pharmacogenetic effects without confounding off-target interactions (further mechanistic analysis—this article extends with in vivo functional data).

Evidence & Benchmarks

• Sulfaphenazole (5.13 mg/kg, i.p., daily, 8 weeks) restored endothelium-dependent vasodilation in db/db diabetic mice by reducing vascular oxidative stress and increasing nitric oxide bioavailability (Turner et al., 2022).
• In pressure injury models (ApoE−/− mice), sulfaphenazole rapidly restored tissue perfusion to pre-injury levels, reduced hypoxia, improved wound closure, and increased wound tensile strength compared to controls (Turner et al., 2022).
• Sulfaphenazole reduced infarct size and improved post-ischemic cardiac function in rat models of cardiac ischemia-reperfusion injury by inhibiting CYP2C-mediated superoxide generation (Turner et al., 2022).
• Sulfaphenazole is chemically defined as 4-amino-N-(1-phenyl-1H-pyrazol-5-yl)-benzenesulfonamide, with a molecular weight of 314.4 and a CAS number of 526-08-9 (APExBIO product page).
• Solubility: ≥13.15 mg/mL in DMSO; ≥9.92 mg/mL in ethanol (with ultrasonic assistance); insoluble in water (APExBIO).
• Long-term stability requires storage at -20°C; solutions are not recommended for extended storage (APExBIO).

Applications, Limits & Misconceptions

Sulfaphenazole is a foundational tool for research in drug metabolism modulation, pharmacogenetics, and vascular endothelial function. Its high selectivity enables studies on CYP2C9-specific pathways, adverse drug reaction mechanisms, and diabetic vascular dysfunction. For example, it is integral in dissecting the interplay between oxidative stress and nitric oxide signaling in vivo (see strategic applications—this article updates with new preclinical benchmarks).

Common Pitfalls or Misconceptions

• Not a Broad-Spectrum CYP Inhibitor: Sulfaphenazole does not significantly inhibit CYP1A1, CYP1A2, CYP3A4, or CYP2C19; its utility is limited to CYP2C9-related research (APExBIO).
• Not for Diagnostic or Therapeutic Use: This product is for research use only and is not intended for clinical or diagnostic applications.
• Limited Water Solubility: Sulfaphenazole is insoluble in water; use DMSO or ethanol (with ultrasound) for solution preparation.
• Stability Constraints: Long-term storage of solutions is not recommended due to potential degradation at higher temperatures or prolonged exposure to light.
• Species Differences: While CYP2C9 inhibition is well-established in humans and rodents, caution is required when extrapolating data across species due to isoform variability (Turner et al., 2022).

Workflow Integration & Parameters

Sulfaphenazole (C4131, APExBIO) is supplied as a solid powder and should be stored at -20°C for stability. For use, dissolve in DMSO (≥13.15 mg/mL) or ethanol (≥9.92 mg/mL, ultrasonic assistance recommended). Typical in vivo protocols employ 5.13 mg/kg intraperitoneally daily for up to 8 weeks in murine models. For in vitro studies, titrate concentration to achieve target CYP2C9 inhibition (Ki = 0.3 ± 0.1 μM). Avoid aqueous buffers for stock solutions. The compound is intended solely for scientific research. For experimental design guidance, see optimization strategies article—this article details vascular endpoints and preclinical validation.

Conclusion & Outlook

Sulfaphenazole remains the reference selective, competitive CYP2C9 inhibitor for drug metabolism and vascular research. Its strong in vivo efficacy, robust selectivity profile, and reliable physicochemical properties make it an indispensable tool for pharmacogenetics, adverse drug reaction studies, and diabetic vascular dysfunction models. APExBIO (C4131) provides validated supply for global research needs. Future directions include expanded use in personalized medicine models and integrated multi-omics studies of CYP2C9 pathways.